Navigation Links
Cyberonics Provides Update on Depression Post-Approval Study
Date:7/24/2009

HOUSTON, July 24 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that the U.S. Food and Drug Administration ("FDA") has approved the company's proposal to amend the protocol of its D-21 post-approval dosing study in depression patients treated with VNS Therapy(TM).

The company submitted a proposal in November 2008 to reduce the number of study subjects from 460 to 330 and completed enrollment of 331 study subjects in February 2009. With this decision from the FDA, the company expects to complete the follow-up on all patients enrolled in the study by March 2010.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate,"
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... CHAPEL HILL, N.C., Sept. 24 As the bio-pharmaceutical ... area of Oncology are tailoring their market education strategies ... their therapeutic area. Leading organizations have found that a ... product launch as KOLs, physicians, and payers in the ...
... WASHINGTON, Sept. 24 OrbusNeich today announced at the ... of patient enrollment in the randomized clinical trial of ... 183 patients included at sites in Asia, Australia, Europe ... this study represents a significant milestone as we look ...
Cached Medicine Technology:Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 3
(Date:8/22/2014)... 2014 Natural Clear Vision , a ... his own vision from legally blind to perfect 20/20 vision ... review. , “There is a huge portion of the ... function, and most people just think that’s the way it ... that can be pretty risky at times,” reports Michaels. “This ...
(Date:8/22/2014)... deletion in advanced non-small cell lung cancer (NSCLC) ... in epidermal growth factor receptor (EGFR) tyrosine kinase ... BIM deletion independently predicts overall survival (OS) of ... activate the programmed cell death also known as ... been detected in 12.8% of the Asian population ...
(Date:8/22/2014)... (RA), a complex autoimmune disease that affects 1 ... not only cope with pain, disability and joint ... work, family life and marital functioning. While many ... and disability is common. In addition, some patients ... or side effects. Because of this, there is ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... BASKING RIDGE, N.J., Oct. 19 Hooper Holmes,Inc. ... a proven, standard,method for acquiring the additional health ... applicants. Mature Assessment reflects the trend of ... increased willingness to insure them.,To address these customers, ...
... Skin Treatment to Treat All ... BARRINGTON, Ill., Oct. 19 Steroids have been in ... must be reasons why,people use steroid products on a regular ... of the human body, and it needs to stay healthy. ...
... Host Conference Call and Webcast Same Afternoon, DENVER, ... of functional foods, beverages and nutritional,supplements, today announced that ... the three and nine months, ended September 30,2007, on ... a teleconference the same afternoon beginning at,4:15 PM Eastern ...
... XI,AN, China, Oct. 19 /Xinhua-PRNewswire-FirstCall/ -- Mr. Weibing ... (OTC,Bulletin Board: SKBI) ("Skystar") will be featured in ... 24, 2007, at 10:30 a.m.,EST. The interview will ... p.m. EST on,October 24. The interview will ...
... drug is given just once per month, experts say , ... treating anemia in patients with severe kidney disease could help ... , Compared with conventional therapy, giving patients an anti-anemia drug ... concluded Dr. Nathan Levin, of the Renal Research Institute in ...
... ... at TCT 2007 ... Oct. 19 Stereotaxis, Inc. (Nasdaq:,STXS) announced today that it will ... at the,Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington,D.C., October 20 to ...
Cached Medicine News:Health News:Hooper Holmes Introduces Mature Assessment 2Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 3Health News:Skystar Bio-Pharmaceutical Announces Upcoming Interview With WallSt.net ( www.wallst.net ) 2Health News:Simpler Anemia Treatment May Help Kidney Patients 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 3Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: